Mineralys Therapeutics

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for hypertension and related cardio-renal-metabolic conditions associated with dysregulated aldosterone. Its research centers on the role of aldosterone in disease and on developing targeted treatment approaches for people whose conditions may be driven by this hormone pathway.

The company’s initial product candidate is lorundrostat (also known as MLS-101), a proprietary, orally administered, selective aldosterone synthase inhibitor. Mineralys is developing it for hypertension, including uncontrolled and resistant hypertension, and has also investigated its potential relevance to chronic kidney disease and obstructive sleep apnea. Lorundrostat was discovered and advanced through Phase 1 by Mitsubishi Tanabe Pharmaceutical Company, now Tanabe Pharma Corporation; Mineralys licensed the compound in 2020.

Mineralys says it was formed in 2019, and its founder is Brian Taylor “BT” Slingsby. The company’s work is grounded in the view that dysregulated aldosterone can contribute to hypertension and related conditions, and that a more targeted approach may help address underlying disease mechanisms. Its stated purpose is to develop targeted medicines for people managing hypertension and related cardio-renal-metabolic disorders.

The company is headquartered in Radnor, Pennsylvania. Mineralys describes itself as a fully remote employer, with employees working from their home locations and periodic in-person meetings and events. Its careers materials characterize the team as experienced, diverse, passionate, and curious, and describe collaboration, inclusion, patient focus, and shared problem-solving as elements of its working culture.

Mineralys also highlights partnerships as part of its approach to research and development. It says it works with, or seeks collaboration with, academic institutions, pharmaceutical companies, and biotechnology firms to support clinical development and biomarker discovery, and it identifies in-licensing and commercial partnerships as areas of interest. These activities complement its internal focus on developing its lead candidate and exploring the biology of aldosterone-related disease.

The company’s stated ambition is to bring targeted therapies to people affected by hypertension and related conditions. Its public materials emphasize the potential health and quality-of-life impact of hypertension and describe a patient-centered approach to drug development. Mineralys is publicly traded under the Nasdaq ticker MLYS.